Nile Therapeutics to raise $1.4 million in stock sale San Francisco Business Times (blog) Nile is focused on cenderitide, its lead drug candidate, meant to treat heart failure. Joshua Kazam is president and CEO of Nile. He took the top job at the company in June 2009. Daron Evans is the company's chief financial officer. NILE THERAPEUTICS, INC. : March 30, 2012 - Nile Therapeutics, Inc. To Raise ... Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering |
